BIOMARKER:

BCR-ABL1 mutation

Entrez ID:

Related biomarkers:

‹

›

BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	ABL001 Sensitive: C2 – Inclusion Criteria	ABL001 Sensitive: C2 – Inclusion Criteria
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + nilotinib Sensitive: C3 – Early Trials	venetoclax + nilotinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + bosutinib Sensitive: C3 – Early Trials	venetoclax + bosutinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + ponatinib Sensitive: C3 – Early Trials	venetoclax + ponatinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + dasatinib Sensitive: C3 – Early Trials	venetoclax + dasatinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Acute Myelogenous Leukemia AML	BCR-ABL1 mutation BCR-ABL1 mutation	Acute Myelogenous Leukemia AML	venetoclax + dasatinib Sensitive: C3 – Early Trials	venetoclax + dasatinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Acute Myelogenous Leukemia AML	BCR-ABL1 mutation BCR-ABL1 mutation	Acute Myelogenous Leukemia AML	venetoclax + ponatinib Sensitive: C3 – Early Trials	venetoclax + ponatinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Acute Lymphocytic Leukemia ALL	BCR-ABL1 mutation BCR-ABL1 mutation	Acute Lymphocytic Leukemia ALL	dasatinib + blinatumomab Sensitive: C3 – Early Trials	dasatinib + blinatumomab Sensitive: C3 – Early Trials